Foretinib inhibits HGF-induced c-Met phosphorylation, inhibits tumour cell growth in hypoxic and normoxic conditions, and has been shown to reduce tumour cell burden in an in vivo model of lung cancer [92]. Here, MET is linked to lung cancer.